Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET

Company Participants

Richard Lepke - Senior Director, Investor Relations
Marianne De Backer - Chief Executive Officer
Mark Eisner - Executive Vice President & Chief Medical Officer
Jason O’Byrne - Executive Vice President & Chief Financial Officer

Conference Call Participants

Paul Choi - Goldman Sachs
Eric Joseph - JPMorgan
Mike Ulz - Morgan Stanley
Gena Wang - Barclays
Alec Stranahan - Bank of America
Nikola Gasic - Leerink
Phil Nadeau - TD Cowen
Patrick Trucchio - H.C. Wainwright & Co.

Operator

[Call starts abruptly]

…Vir's Third Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. [Operator Instructions]

I will now turn the call over to Rich Lepke, Senior Director, Investor Relations. You may begin, Mr. Lepke.

Richard Lepke

Thank you and good afternoon. With me today are Dr. Marianne De Backer, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; and Jason O'Byrne, our Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Forms 10-K, 10-Q and 8-K.

I will now turn the call over to our CEO, Marianne De Backer.

Marianne De Backer

Thank you, Rich. Good afternoon, everyone and thank you for joining us today. I'm pleased to provide an update on the significant progress we've made this quarter, beginning with the successful closing of our exclusive worldwide licensing agreement with Sanofi. This landmark agreement includes 3 clinical stage masked T-cell engagers and use of Sanofi's proprietary PRO-XTEN protease-cleavable masking platform for oncology and infectious diseases.

This strategic move aligns seamlessly with our mission to use the power of the immune system to fight disease. We believe that the 3 dual-masked T cell engagers VIR-5818 for HER2, VIR-5500 for PSMA and VIR-5525 for EGFR have the potential to be best-in-class therapies. These investigational treatments aim to minimize toxicity challenges typically associated with T-cell engagers, allowing for higher dosing and thereby enhancing efficacy.